Abstract
Doses of 600 mg and 1200 mg of D(-)penicillamine daily were superior to a standard regimen of therapy in rheumatoid arthritis. The higher dose did not produce significantly greater therapeutic benefit in the group of patients so treated, although individual patients sometimes improved more. The frequency of rashes, blood dyscrasias, and withdrawals from the trial increased withe dosage. It is concluded that D(-)penicillamine is a useful treatment that the daily dose should be as low as possible, and that it should be increased at infrequent intervals only, with due regard to the likelihood of further improvement in relation to an increased risk of adverse reactions.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Day A. T., Golding J. R., Lee P. N., Butterworth A. D. Penicillamine in rheumatoid disease: a long-term study. Br Med J. 1974 Feb 2;1(5900):180–183. doi: 10.1136/bmj.1.5900.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Golding J. R., Wilson J. V., Day A. T. Observations on the treatment of rheumatoid disease with penicillamine. Postgrad Med J. 1970 Oct;46(540):599–605. doi: 10.1136/pgmj.46.540.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- JAFFE I. A. Intra-articular dissociation of the rheumatoid factor. J Lab Clin Med. 1962 Sep;60:409–421. [PubMed] [Google Scholar]